This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase III, randomized, 3-arm, open-label study comparing the effectiveness of the following three regimens for the initial treatment of HIV infection: a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen (efavirenz (EFV) + stavudine-extended release (d4T XR) [or zidovuidine (ZDV) or tenofovir (TDF)] + epivir (3TC), a (ritonavir) RTV-enhanced protease inhibitor (PI)-based regimen (lopinavir LPV/RTV + d4T XR [or ZDV or TDF] + 3TC), and, a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen (EFV + LPV/RTV). This study will enroll 660 HIV-1-infected, ARV (antiretroviral)-naive male and female subjects >18 years of age.
Showing the most recent 10 out of 563 publications